75 results
8-K
EX-99.1
UBX
Unity Biotechnology Inc
14 May 24
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results
5:00pm
March 31, 2023.
Research and development expenses decreased by $2.1 million, to $3.7 million for three months ended March 31, 2024 from $5.8 million … for the three months ended March 31, 2023. The decrease was primarily due to decreases of $1.6 million in direct research and development expenses mainly
8-K
EX-99.1
UBX
Unity Biotechnology Inc
15 Apr 24
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
, 2022. The decrease was primarily due to decreases of $7.3 million in direct research and development expenses mainly due to the completion of our … -related costs primarily due to the sublease of our East Grand facility, and $0.3 million in laboratory. Research and development expenses decreased by $4.5
424B3
dqf 6jr6zqfgf69
8 Dec 23
Prospectus supplement
4:39pm
8-K
EX-99.1
nj60zwrxhqoxjfakb4o
13 Nov 23
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
jn9 ds9kz5yswtk7o2
8 Aug 23
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results
4:04pm
8-K
EX-99.1
4vso37uviu1j7o76g2sp
9 May 23
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
91wp9t32g59f2g
8 Nov 22
UNITY Biotechnology, Inc. Reports Third Quarter 2022
4:09pm
424B5
c667bh
25 Oct 22
Prospectus supplement for primary offering
9:39pm
424B5
6sowb e3n
19 Aug 22
Prospectus supplement for primary offering
8:42am